Disclaimer:
This blog is for informational purposes only and should not be taken as medical advice. Content is sourced from third parties, and we do not guarantee accuracy or accept any liability for its use. Always consult a qualified healthcare professional for medical guidance.
Mesothelioma is a rare, aggressive cancer from mesothelial cells lining the pleura (80%, pleural), peritoneum (10-20%), pericardium, or tunica vaginalis. Epithelioid (60%, better prognosis), sarcomatoid (20%, aggressive), or biphasic subtypes. In 2025, ~3,000 US cases, linked to asbestos, median age 72, men 4:1.
Pleural mesothelioma causes chest pain, shortness of breath, cough, pleural effusion, fatigue, weight loss, night sweats. Peritoneal causes abdominal pain, ascites, bowel obstruction. Symptoms develop 20-50 years post-exposure, mimicking pneumonia or IBS.
Asbestos exposure (70-80% of cases) causes inflammation/mutations (BAP1, NF2). Radiation, erionite, or genetics (BAP1 syndrome) contribute. In 2025, genomic studies show immune evasion.
Diagnosis uses imaging (CT, PET for pleural thickening/effusion), biopsy (thoracoscopy/percutaneous), immunohistochemistry (calretinin+, WT1+), and molecular testing (BAP1 loss). In 2025, liquid biopsies detect ctDNA.
Multimodal: surgery (pleurectomy/decortication or extrapleural pneumonectomy), chemotherapy (pemetrexed + cisplatin), radiation. Immunotherapy (nivolumab + ipilimumab) is first-line, with 40% response. In 2025, ADCs target mesothelin.
In 2025, median survival is 12-21 months, 5-year 10%. Immunotherapy extends to 18 months. By 2030, vaccines and gene therapy could achieve 30% 5-year survival.
Mayo Clinic’s “Mesothelioma – Symptoms and causes” for symptoms; Cleveland Clinic’s “Mesothelioma: Symptoms, Causes, Diagnosis & Treatment” for treatment; NCI’s “Malignant Mesothelioma Treatment” for prognosis; PMC’s “Mesothelioma: An Update on Diagnosis and Treatment” for updates; OncoDaily’s “Mesothelioma: Symptoms, Diagnosis, Treatment” for details; American Lung Association’s “Mesothelioma Symptoms, Causes and Risk Factors” for risks; Cancer Research UK’s “Mesothelioma” for research; Asbestos’s “Mesothelioma Symptoms” for symptoms; Mesothelioma.com’s “Mesothelioma” for overview; Healthline’s “Mesothelioma: Types, Symptoms, Causes, Diagnosis” for diagnosis.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
1. Scan at your preferred center.
2. Written report from a specialist radiologist sent via email.
3. Access and download your scan images digitally.
4. Upon request, we can send the report and images to your doctor or hospital.
5. For self-referred patients, there is an additional charge of £30, which includes scan referral and a discussion with a private GP before and after the scan